urc mondor

Unité de Recherche Clinique Henri Mondor

Tolerance and efficacy of platelet-rich plasma injections in Peyronie's disease: Pilot study.

Schirmann A, Boutin E, Faix A, Yiou R Prog Urol. 2022;32(12):856-861.

<p><b>INTRODUCTION: </b>Platelet-rich plasma (PRP) injections are increasingly proposed for the treatment of Peyronie's disease since the discontinuation of Xiapex® despite poorly understood results.</p><p><b>OBJECTIVES: </b>Evaluation of the tolerance and efficacy of intra-plate PRP injections in patients with Peyronie's disease.</p><p><b>METHODS: </b>Three intra-plate injections of PRP were performed 15 days apart in 17 patients with Peyronie's disease. The Peyronie's Disease Questionnaire (PDQ) and the measurement of the angle of curvature of the erect penis were assessed before treatment and then 1, 3 and 6 months after treatment. Erectile function was assessed by different questionnaires (IIEF-EF, EHS, SEP, sexual discomfort score).</p><p><b>RESULTS: </b>No side effects were noted during the study period. Three months after treatment, all three PDQ domains were significantly improved (P=0.002; P=0.015; P=0.017 respectively). The angle of curvature of the penis was significantly decreased by 11.8° with a mean angle of 40.4° before treatment and 28.6° after (P=0.007). The IIEF-EF score was significantly improved after treatment (mean preoperative value: 10.67) with a gain of 5 points at months 1 and 6 (P=0.01 and P=0.036 respectively) and 7 points at month 3 (P=0.04).</p><p><b>CONCLUSION: </b>Our initial experience suggests that PRP injections for Peyronie's disease are safe. Although the limited data is suggestive of efficacy, a placebo control will be required for confirmation.</p>

MeSH terms: Humans; Male; Penile Induration; Penis; Pilot Projects; Platelet-Rich Plasma; Treatment Outcome
DOI: 10.1016/j.purol.2022.05.004